Pulmonary hypertension and systemic sclerosis;Hipertensão pulmonar e esclerose sistêmica

Jornal Brasileiro de Pneumologia

Volumn 31, Issue , 2005, Pages

[No Author Info available]

Author keywords

Hypertension, pulmonary; Mass screening; Scleroderma, systemic complications

Indexed keywords

EID: 47649127327     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132005000800006     Document Type: Article

References (17)

1. Marques Neto JF, Sampaio-Barros PD. Esclerose sistê-mica. Em Moreira C, Carvalho MAP. Reumatologia: diagnóstico e tratamento. 2a ed. Rio de Janeiro: Medsi; 2001. p. 465-88.
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5.
3. Medsger TA Jr. Classification, prognosis. In: Clements PJ, Furst DE editors. Systemic sclerosis. 2th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p.17-28.
4. Denton CP, Black C. Pulmonary vascular involvement in systemic sclerosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p.184-94.
5. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62(2):97-9.
6. Denton CP, Cailes JB, Philips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997;36(2):239-43.
7. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001;40(4):453-9.
8. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-93.
9. Azevedo ABC, Sampaio-Barros PD, Torres RM, Moreira C. Avaliação da prevalência de hipertensão pulmonar na esclerose sistêmica. Rev Bras Reumatol. 2004;44(1): 31-9.
10. Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43(4):461-6.
11. Phlippoteau C, Brenot F, Blétry O, Simmonneau G, Duroux P. Etude des drogues vasodilatatrices dans l'hypertension artérielle pulmonaire dês sclérodermies systemiques. Rev Mal Respir. 1990;7(3):249-54.
12. Morgan JM, Griffiths M, du Bois RM, Evans TW. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest. 1991;99(3):551-6.
13. Kubo M, Vensak J, Dauber J, Keenan R, Griffith B, McCurry K. Lung transplantation in patients with scleroderma. J Heart Lung Transplant. 2001;20(2):174-5.
14. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6): 425-34.
15. Launay D, Hachulla E, Hatron PY, Goullard L, Onimust T, Robin S, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol. 2001; 28(10):2252-6.
16. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420-7.
17. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124(1): 247-54.